Guessing $50m+ sales is going to come much faster than most of us expect, especially with the significant expansion of the sales force. Clearly a best in class device that is significantly differentiated from peer products, combine the high revenue growth with cash flow positive (expected in FY25) and you quickly see just how undervalued this is at the current market cap.
And that's not even thinking about 2RT and the other R&D which are potentially many many multiples larger than iTrack Advance
Nova Eye Medical (EYE) Discussion, page-2447
-
- There are more pages in this discussion • 741 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add EYE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
24.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $54.91M | |||
| Open | High | Low | Value | Volume |
| 24.0¢ | 24.5¢ | 24.0¢ | $110.1K | 458.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 432506 | 23.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 24.0¢ | 169560 | 3 |
View Market Depth
| Last trade - 16.10pm 25/07/2024 (20 minute delay) ? |
| EYE (ASX) Chart |